Kornimate/medical-research-clean huggingface dataset:
the effect of high-flow nasal oxygen flow rate on gas exchange during apnoea

Conditions: Apnea; Respiration; Arrest; Anesthesia

Summary: apnoeic oxygenation refers to oxygenation that occurs through the insufflation of oxygen into the lungs in the absence spontaneous respiration or positive pressure ventilation. it is used to extend the time to desaturation at induction of anaesthesia and as a primary oxygenation technique during airway surgery. the impact of high-flow nasal oxygen flow rate selection on gas exchange is poorly understood. participants in this study will be randomised to receive a certain nasal oxygen flow rate during apnoea and its effect on gas exchange will be measured by blood gas analysis.

apnoeic oxygenation with high-flow nasal oxygen has been proposed to result in carbon dioxide clearance. however, this has been poorly quantified. this study will compare use of nasal oxygen at different flow rates during apnoea with that of a control that does not receive nasal oxygen. participants are anaesthetised after standardised pre-oxygenation with high-flow nasal oxygen, after which they will receive one of three nasal oxygen flow rates (0, 70, 120 l/min). the rate of carbon dioxide elevation will be measured by arterial blood gas analysis after the onset of apnoea and compared between the three groups to discern the relative rates of carbon dioxide clearance after the first minute of apnoea. the effect of nasal oxygen flow rate on oxygenation will also be measured.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * asa 1 or 2 * receiving a general anaesthetic for non-emergent surgery exclusion criteria: * asa score ≥3 * bmi ≥ 30 kg/m2 * nasal obstruction * baseline spo2 ≤95% on room air * anticipated difficult airway management * requirement for awake intubation * pregnancy * positive pcr test for coronavirus in preceding 14 days.
efficacy and safety of peri-operative pregabalin after radical cystectomy

Conditions: Postoperative Pain Following Radical Cystectomy

Summary: this study compares analgesic efficacy, and safety of three different doses of peri-operative pregabaline to placebo following radical cystectomy.


Eligibility criteria:
inclusion criteria: * sixty patients between the ages of 18 and 60 years. * american society of anesthesiologists (asa) i-ii physical status. * undergoing radical cystectomy under general anesthesia. exclusion criteria: * patients with a history of drug or alcohol abuse. * patients with chronic pain or daily intake of analgesics. * uncontrolled diabetes mellitus. * uncontrolled hypertension. * atherosclerotic heart disease. * seizures. * impaired kidney or liver functions, * patients with body mass index ≥35 kg/m2, and whom * patients that could not control a patient controlled analgesia (pca) device.
effects of deep breathing exercise on pulmonary function, perceived stress and physical fitness among healthy smokers

Conditions: Cigarette Smoking

Summary: effects of deep breathing exercise on pulmonary function, perceived stress and physical fitness among healthy smokers.

smoking is injurious to health as cigarette contains harmful substances that cause different life threatening diseases, like bronchitis, asthma, chronic obstructive pulmonary disease (copd), cardiovascular diseases etc. during normal breathing, oxygen is supplied to the body through blood circulation. but, in smokers, carbon monoxide (co) is supplied to body instead of oxygen, resulting in respiratory issues, like breathlessness and coughing, in acute stages . smoking decreases lung capacity, as it contains acidic substances which start damaging the lining of the bronchi and bronchioles due to which they become inflamed and infected, resulting into coughing, shortness of breath and chest pain that leads towards chronic bronchitis. this study will contribute our young smokers as they are adherent to smoking and its difficult for them to quit smoking. as their physical activity is limited, individuals under stress condition and with pulmonary complications so impact of this research is that along with helping smokers to quit smoking also applying alternative strategies to minimize complication and improve quality of life. and these alternative strategies include such activities that performed easily at home and do not require much effort or no need to go to gym or any other place to perform these exercises.

Eligibility criteria:
inclusion criteria: * only male healthy smoker. * age: 20 - 30 years. * participants had a minimum smoking history of 5 years. * subject without any chronic pulmonary complication. exclusion criteria: * smokers with any pulmonary disease, acute infections, other systemic disease. * chest deformity or any disability. * history of any surgery. * not willing to participate.
oral vitamin d substitution weekly or monthly and adherence

Conditions: Vitamin D Deficiency

Summary: vitamin d deficiency (defined as 25(oh)-vitamin d serum level \<50 nmol/l) is cured with supplementation by mouth. national guidelines recommend the administration of 800 iu cholecalciferol daily for an effective treatment, especially during the winter (poor sun exposition). commercially available pharmaceutical forms are liquid in switzerland (drops) and solid forms in germany (tablets and capsules). because therapeutic range of vitamin d3 is wide and toxicity is seldom reached, even after the consumption of 200'000 iu, and because the administration of 8 drops daily is inconvenient, weekly and monthly administrations of the cumulative amount (i.e., 5'600 iu weekly or 24'000 iu monthly) have been investigated. both administration schedules are therapeutic equivalent. the study aims to investigate which form (liquid or solid) and which schedule (weekly or monthly) procure the highest adherence behavior with outpatients under polypharmacy i.e., with 4 or more medications daily. the investigators will use commercially available swiss and german products.

intervention study in patients with serum vitamin d \<50 nmol/l and polypharmacy, defined as ≥4 medicaments/day. treatment duration: 6 months. treatment groups are defined as lm (liquid monthly 24'000 iu); lw (liquid weekly 5'600 iu); sm (solid monthly 20'000 iu) and sw (solid weekly 5'600 iu). cross-over design with identical form (liquid or solid) and switching frequence, i.e. from weekly to monthly treatment and vice versa, for 3 months each.

Eligibility criteria:
inclusion criteria: * vitamin d deficiency by serum level \<50 nmol/l * polypharmacy defined as 4 daily medicines or more * speaking german or swiss german exclusion criteria: * hypercalcaemia * substitution treatment with cholecalciferol in the past 3 months * medication intake provided by a third person and not by the patient himself

Keywords: adherence to medication electronic monitoring
in-patient study in schizophrenic patients

Conditions: Schizophrenia

Summary: this study is a placebo-controlled study to assess the safety and tolerability of a novel antipsychotic medication, (773812) when given to schizophrenic patients for twenty-eight days. assessments include blood sampling to determine drug concentrations, psychiatric assessments while under treatment, and movement assessments to evaluate potential side effects.


Eligibility criteria:
inclusion criteria: * must have schizophrenia that has been stable for at least three months. * willing to discontinue current anti-psychotic medications (under supervision) prior to the study. * willing to live at the study center for a total of 38 days and then return for three follow-up visits. exclusion criteria: * taking medications for conditions other than schizophrenia. * history of alcohol or drug abuse within six months of the study, and their alcohol consumption must meet moderate guidelines.

Keywords: schizophrenia safety tolerability pharmacokinetics
exercise testing for early stage breast cancer patients receiving radiation treatment

Conditions: Breast Cancer; Fatigue

Summary: many patients receiving radiation therapy for breast cancer experience fatigue although doctors do not fully understand why. the purpose of this study is to test if patients who experience fatigue during radiation treatment for breast cancer have changes in their capability to perform exercise on a treadmill.


Eligibility criteria:
inclusion criteria: * female * ecog performance status 0 or 1 * medical clearance from attending radiation oncologist or medical oncologist to undergo a symptom-limited cpet * currently undergoing intact breast radiotherapy for early stage breast cancer (including tisn0, t1n0, t2n0) or has completed intact breast rt in the last 3 months. * receiving or received a prescribed dose of 4240 cgy in 16 fractions to the whole breast without treatment directed at nodal basins. patients may also be receiving or have received a boost to the lumpectomy bed at the discretion of the treating physician. * subjects may be treated in the supine or prone position at the discretion of the treating physician. * subjects may be treated with or without a deep inspiratory breath hold technique at the discretion of the treating physician. * identified by the treating radiation oncologist as having significant treatment-related fatigue or minimal treatment-related fatigue and not simply baseline fatigue. a score of "0" on the rtog fatigue scale will be considered minimal fatigue, while a score of "2" or greater will be considered significant fatigue (moderate fatigue causing difficulty performing some adls). exclusion criteria: * currently undergoing post-mastectomy radiation * has received chemotherapy previously or has a plan to receive chemotherapy during the timeframe of study assessment. * any of the following absolute contraindications to cpet, as per american thoracic society (ats) recommendations * acute myocardial infarction (within 3-5 days of any planned study procedures) * unstable angina * uncontrolled arrhythmia causing symptoms or hemodynamic compromise * recurrent syncope * active endocarditis * acute myocarditis or pericarditis * symptomatic severe aortic stenosis * uncontrolled heart failure * acute pulmonary embolus or pulmonary infarction within 3 months of any planned study procedures * thrombosis of lower extremities * suspected dissecting aneurysm * uncontrolled asthma * pulmonary edema * room air desaturation at rest ≤ 85% * respiratory failure * acute non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis) * mental impairment leading to inability to cooperate

Keywords: exercise radiation treatment 16-941
testing the effectiveness of henna on managing ppe

Conditions: Palmar-plantar Erythrodysesthesia (PPE)

Summary: the palmar-plantar erythrodysesthesia (ppe) is the only clinical adverse event that commonly occurs with capecitabine and/or pegylated liposomal doxorubicin treatment and it warrants special attention because it is the most common dose-limiting toxicity. this study is designed to test the effectiveness of a henna treatment protocol in the management of capecitabine and/or pegylated liposomal doxorubicin induced palmar-plantar erythrodysesthesia.

this will be a randomized double-blind, placebo-controlled study with 80 cancer patients that will receive chemotherapy treatment with capecitabine and/or pegylated liposomal doxorubicin. the selection of potential participants will be based on pre-determined inclusion and exclusion criteria. patients will be randomly allocated either to the treatment group or the placebo group. treatment will be delivered twice a week and assessments will take place at 2, 3, 4, 5 and 6 weeks. the intervention group will receive the application of henna to the hands and/or feet of the patients and the control group will receive the placebo. at both baseline and follow-up, patients in both groups will be assessed for their degree of palmar-plantar erythrodysesthesia, the quality of life, the need for dose-limiting due to ppe and pain intensity using standardized rating scales. data will be analysed with inferential and descriptive statistics.

Eligibility criteria:
inclusion criteria: * adult cancer patients (\>18) * patients receiving capecitabine and/or pld as monotherapy or in combination with other agents * patients that will experience ppe grade 1 or above * willing to participate * ability to complete the psychometric assessments. * a performance status of two or less on the eastern cooperative oncology group (ecog) exclusion criteria: * patients with hypersensitivity to natural henna. * patients with pre-existing dermatological condition affecting the hands or feet that may limit the interpretation of results * patients on pyridoxine or nicotine patches * patients with a previous history of ppe * patients whose chemotherapy was discontinued for more than a week

Keywords: hand-foot syndrome palmar-plantar erythrodysesthesia capecitabine pegylated liposomal doxorubicin henna
a study to evaluate the effect of the combination of pertuzumab with carboplatin-based standard chemotherapy in patients with recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: this study will evaluate the efficacy and safety of pertuzumab in combination with carboplatin-based standard chemotherapy in patients with platinum-sensitive recurrent ovarian cancer. the anticipated time on study treatment is 3-12 months.


Eligibility criteria:
inclusion criteria: * histologically confirmed ovarian, primary peritoneal, or fallopian tube cancer; * only 1 previous regimen, which must be platinum-based; * platinum-sensitive disease which is defined by a progression-free interval of greater than 6 months after completion of platinum-based chemotherapy. exclusion criteria: * previous radiotherapy; * previous treatment with an anti-cancer vaccine or any targeted therapy; * major surgery or traumatic injury within 4 weeks of study; * history or evidence of central nervous system metastases.
dual-task performance in young-onset pd

Conditions: Early Onset Parkinson Disease; Early Stage Parkinson Disease

Summary: this study aimed to investigate the effects of game based dual-task training with treadmill on executive function and dual-task performance in individuals with early-onset pd and discuss the correlation between the change values of executive function and dual-task performance after training. besides, investigate cortical activation after training.


Eligibility criteria:
inclusion criteria: * diagnosed as pd and hoehn and yahr stage between 1\~3 * age between 20 to 80 * able to walk 10 m independently without an assistive device * a score of greater than or equal to 24 on the mini-mental state examination (mmse) * in stable medical condition allowing participation in the testing protocol and intervention exclusion criteria: * any comorbidity or disability other than pd that would preclude gait training * any uncontrolled health condition for which exercise was contraindicated * any neurological or orthopedic disease that might interfere with the study * server freezing of gait, fog questionnaire \> 15

Keywords: executive function dual-task performance dual-task training
pain modulation - experimental assessments using different modalities

Conditions: Low Back Pain; Compare Pain Modulation Assessments in Pain-free Cohorts

Summary: the goal of this study is to investigate how different painful stimuli are processed and modulated in the nervous system. in various pain conditions, including low back pain, often no specific source can be identified as the cause of the pain. scientific findings point towards a possible involvement of sensitization processes in the central nervous system (spinal cord and brain) that can contribute to the development and persistence of chronic pain. there is a need for reliable and well established experimental methods to better investigate and understand these processes. frequently used methods comprise the application of thermal, mechanical or electrical stimulations. these modalities are processed in different parts of the nervous system, each allowing its own conclusions. this can be an advantage, but it also poses a challenge regarding comparability and generalizability of obtained results. this study aims to apply and compare various experimental methods in people without and people with low back pain and shed light on the methodological differences. in the future, this could enable better identification and characterization of sensitization processes in the nervous system and build the basis for individually adapted, mechanism-targeted treatments with better patient outcomes.


Eligibility criteria:
inclusion criteria: * german or english proficiency * informed consent * primary pain complaint localized between the 12th rib and the gluteal fold * low back pain for more than one week * low back pain clinically not attributable to "red flags" (including infection, trauma, fractures, inflammatory) exclusion criteria: * unable to give informed consent (e.g. due to language problems) * any neurological condition * any major medical or psychiatric condition (e.g. severe heart disease, diabetes, autoimmune disorders, major depressive disorder), any chronic pain condition other than low back pain * pregnancy * radiating pain below knee level (radicular pain)

Keywords: low back pain temporal summation of pain conditioned pain modulation
quality of life outcomes of humira in rheumatoid arthritis (ra), psoriatic arthritis (psa), ankylosing spondylitis (as) after unsustainable response to biologicals and disease modifying antirheumatic drugs

Conditions: Rheumatoid Arthritis; Ankylosing Spondylitis; Psoriatic Arthritis

Summary: the aim of this post-marketing observational study is to obtain further data on the evaluation of quality of life outcomes of humira® in routine clinical use in patients with rheumatoid arthritis (ra), psoriatic arthritis (psa) or ankylosing spondylitis (as) after unsustainable clinical response to disease modifying antirheumatic drugs (dmard) and or biological disease modifying antirheumatic drugs (bdmard). treatment strategies in moderate to severe rheumatoid arthritis, psoriatic arthritis and in severe active ankylosing spondylitis commonly consist of introducing biologics after conventional disease modifying antirheumatic drugs or non steroidal antiinflammatory drugs fail. although biologic disease modifying antirheumatic drugs are generally well-tolerated, intolerances may develop or efficacy may diminish, at which time another biologic disease modifying antirheumatic drug might be considered. this study shall evaluate the quality of life outcomes of humira®, given after conventional disease modifying antirheumatic drugs and or non antiinflammatory drug failures and or after biological disease modifying antirheumatic drug failures . failure in this context means primary or secondary loss of efficacy or intolerance to the initial agent.


Eligibility criteria:
inclusion criteria: * patients age greater than or equal to 18 * patients must fulfill international and national guidelines for use of a bdmard in ra, psa and as (chest x-ray and purified protein derivative (ppd) skin test negative for tuberculosis). in addition one of the following criteria must be fulfilled: * unsatisfactory dmard response defined as failure to treatment with at least two dmards including methotrexate in patients with ra or psa * unsatisfactory nsaid response in patients with as or * unsatisfactory response to prior bdmards (in this case patients must have received bdmards at least 12 weeks before visit 1) in patients with ra or psa or as. exclusion criteria: * patients who meet contraindications as outlined in the latest version of the humira syringe® summary of product characteristics (smpc) and humira pen® smpc * patients participating in another study or clinical trial.

Keywords: monoclonals antibodies ankylosing spondylitis antirheumatic agents quality of life adalimumab rheumatoid arthritis psoriatic arthritis
mobile gaming app to improve child nutrition in nigeria

Conditions: Child Malnutrition; Behavior, Maternal

Summary: undernutrition among children born to teenage mothers deserves urgent attention in nigeria, where 27.2% of girls (15-19 years) living in rural areas have begun childbearing. the overall goal of this study is to develop, validate and evaluate the effects of a mobile gaming app on the infant and young child feeding practices of teenage mothers, and the nutritional status of children (0 - 2 years).

undernutrition among children born to teenage mothers deserves urgent attention in nigeria, where 27.2% of girls (15-19 years) living in rural areas have begun childbearing. pregnancy elevates the nutrient needs of teenage girls due to competing requirements for fetal development, and growth and maturity in the adolescent mother. the resultant children have a higher likelihood of underweight (13-fold), stunting (8-fold) and wasting (3-fold), and are over 50% more likely to die within the first month of birth, as compared to children of older mothers. previous studies have found positive associations between maternal education/knowledge and optimum infant and young child feeding (iycf) practices. childbirth results in a sharp increase in the responsibilities and work burden of teenage mothers, negatively impacting capacity and self-efficacy for adequate child feeding. furthermore, attempts to improve iycf practices often target older women. the overall goal of this study is to develop, validate and evaluate the effects of a mobile gaming app on the infant and young child feeding practices of teenage mothers. a secondary goal is to evaluate the anthropometric and dietary and plasma levels of microminerals of children, 0 - 24 months of age. a mobile app will be developed and validated. it will feature an interactive role-play game on recommended iycf practices that will help educate teenage mothers about feeding young children. a 6-month randomized controlled trial (rct) will be conducted in 266 predominantly low-income mother-child dyads (0 - 24 months) from nigeria. this rct will compare the influence of the babythrive app vs controls who receive a delayed intervention. it will include knowledge and practices regarding exclusive breastfeeding, introduction to solid/semi-solid foods, meal frequency, dietary diversity and amount of food consumed of teenage mothers. anthropometric measurements and plasma ferritin and zinc of children also will be evaluated.

Eligibility criteria:
inclusion criteria: * teenage mothers with children aged 0 - 24 months exclusion criteria: * children with acute infections, metabolic or feeding issues * mothers younger than 14 years of age * hiv-positive mothers